ARC Clinical Research Studying Anti-Flu Drug in High-Risk Patients
February 15, 2018
ARC Clinical Research has been studying a new drug to fight the flu in high-risk patients, with the goal of being able to offer another flu treatment choice to patients in the future.
The hope is that this drug will provide a choice for viruses that don’t respond to Tamiflu, said Dr. Anurekha Chadha, ARC Rheumatologist and Medical Director of ARC Clinical Research, interviewed for a story in the Austin American-Statesman.
The study is important, she went on to say in the article, because patients who are at high risk tend to get sicker. Patients interested in enrolling in the study can visit the ARC Clinical Research website for more information.